Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 6, 2007, Pages

  Fujihara, Clarice Kazue ^a   Malheiros, Denise M A C ^a   Zatz, Roberto ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratorio de Fisiopatologia Renal   (Brazil)

Author keywords

5 6 nephrectomy; Chronic kidney disease; Chronic renal insufficiency; Thiazide diuretics

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MORPHOLOGY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; WISTAR RAT; ANIMAL; BLOOD FLOW; BLOOD PRESSURE; DRUG EFFECT; DRUG POTENTIATION; FOCAL GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; NEPHRECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TAIL; VASCULARIZATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG SYNERGISM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HYDROCHLOROTHIAZIDE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; NEPHRECTOMY; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; RENAL CIRCULATION; TAIL;

EID: 34447632466     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00521.2006     Document Type: Article

References (41)

1. Akai Y, Homma T, Burns KD, Yasuda T, Badr KF, Harris RC. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol Cell Physiol 267: C482-C490, 1994.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002.
3. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82: 1757-1768, 1988.
4. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
5. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 20: 349-353, 2005.
6. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 30: 865-870, 2004.
7. Fujihara CK, Malheiros DM, Zatz R, Noronha IL. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519, 1998.
8. Fujihara CK, Noronha IL, Malheiros DM, Antunes GR, Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11: 283-290, 2000.
9. Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67: 1913-1924, 2005.
10. Goncalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, De Nucci G, Zatz R. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 286: F945-F954, 2004.
11. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996.
12. Hirakata M, Kaname S, Chung UG, Joki N, Hori Y, Noda M, Takuwa Y, Okazaki T, Fujita T, Katoh T, Kurokawa K. Tyrosine kinase dependent expression of TGF-beta induced by stretch in mesangial cells. Kidney Int 51: 1028-1036, 1997.
13. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 66: 1-9, 2004.
14. Ibrahim HN, Hostetter TH. Role of dietary potassium in the hyperaldosteronism and hypertension of the remnant kidney model. J Am Soc Nephrol 11: 625-631, 2000.
15. Jepsen FL, Mortensen PB. Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function. A quantitative study. Virchows Arch 383: 265-270, 1979.
16. Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Acosta JH. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16: 1909-1919, 2005.
17. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994.
18. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49: 666-678, 1996.
19. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995.
20. Kwon TH, Frokiaer J, Fernandez-Llama P, Maunsbach AB, Knepper MA, Nielsen S. Altered expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. Am J Physiol Renal Physiol 277: F257-F270, 1999.
21. Lacourciere Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide vs. hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 16: 1036-1042, 2003.
22. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771, 1992.
23. Mackie FE, Campbell DJ, Meyer TW. Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int 59: 1458-1465, 2001.
24. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 14: 263-269, 2000.
25. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31: 752-759, 1987.
26. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693-1701, 1999.
27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
28. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein. Primary report of the Val-MARC trial. Hypertension In press.
29. Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, Patterson D, Narins RG. Cyclic stretching force selectively upregulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 148: 1915-1923, 1996.
30. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90: 1932-1943, 1992.
31. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002.
32. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55: 945-955, 1999.
33. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 27: 578-587, 2005.
34. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT1 and AT2 receptors. Am J Pathol 158: 1743-1756, 2001.
35. Takaya K, Koya D, Isono M, Sugimoto T, Sugaya T, Kashiwagi A, Haneda M. Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 284: F1037-F1045, 2003.
36. Uzu T, Harada T, Namba T, Yamamoto R, Takahara K, Yamauchi A, Kimura G. Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 23: 861-865, 2005.
37. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 47: 1-9, 1980.
38. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46: 584-590, 2005.
39. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.
40. Zhou X, Matavelli LC, Ono H, Frohlich ED. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 289: F871-F879, 2005.
41. Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 45: 233-239, 2005.